Appeals court grants stay on Praluent injunction

A federal appeals court granted a motion to stay a permanent injunction blocking U.S. sales of Praluent alirocumab from Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN). Last month, a district court judge granted the injunction to Amgen Inc. (NASDAQ:AMGN),

Read the full 403 word article

User Sign In